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Natural killer (NK) cells comprise a heterogeneous
population of cells important for pathogen defense
and cancer surveillance. However, the functional sig-
nificanceof this diversity is not fully understood.Here,
we demonstrate through transcriptional profiling
and functional studies that the activating receptor
DNAM-1 (CD226) identifies two distinct NK cell
functional subsets: DNAM-1+ and DNAM-1NK cells.
DNAM-1+ NK cells produce high levels of inflam-
matory cytokines, have enhanced interleukin 15
signaling, and proliferate vigorously. By contrast,
DNAM-1 NK cells that differentiate from DNAM-1+
NK cells have greater expression of NK-cell-recep-
tor-related genes and are higher producers of MIP1
chemokines. Collectively, our data reveal the exis-
tence of a functional program of NK cell maturation
marked by DNAM-1 expression.INTRODUCTION
Natural killer (NK) cells are innate lymphocytes involved in the
immune surveillance of cancer and the control of early infec-
tions (Spits et al., 2013; Vesely et al., 2011). NK cells express
a wide range of activating and inhibitory receptors, allowing
them to recognize and kill infected or transformed cells (Vivier
et al., 2008). Upon activation, NK cells quickly produce various
chemokines and cytokines such as MIP1a and MIP1b and
IFN-g, TNFa, IL-6, and GM-CSF, respectively (Colucci et al.,
2003). This early source of inflammatory mediators alerts other
immune components against potential dangers and provides a
critical link between innate and adaptive immune responses
(Raulet, 2004).Despite some common features, NK cells represent a hetero-
geneous population of cells with diverse receptor repertoires
and distinct maturation levels (Hayakawa et al., 2006). Several
NK cell subsets with specialized functions have been described
in humans and mice, suggesting that the functional diversity dis-
played by NK cells is governed by distinct NK cell subsets with
discrete effector functions (Huntington et al., 2007a). In mice,
two distinct populations of NK cells can be defined based on
CD11b expression (Kim et al., 2002). CD11b NK cells predom-
inate in fetal and neonatal mice, display an ‘‘immature’’ pheno-
type, and demonstrate a high rate of homeostatic proliferation
but poor cytotoxic functions. By contrast, the CD11b+ NK cells
represent the main mature subset in adult mice, express high
levels of Ly49 receptors, and display higher cytotoxic functions
compared to the CD11b NK cells. NK cell development can
be further divided using CD27 expression (Chiossone et al.,
2009; Hayakawa and Smyth, 2006). In addition, the expression
of KLRG1 on mature NK cells allows the identification of a termi-
nal stage of NK cell differentiation associated with reduced
proliferation and effector functions (Huntington et al., 2007b).
Despite these advances, there is still extensive work required
to characterize the different NK cell populations in mice and
humans in regards to their specialized effector functions.
DNAM-1 (CD226) is an adhesion molecule triggering the cyto-
toxicity of NK and CD8+ T cells upon interaction with its ligands
CD155 and CD112 (Bottino et al., 2003; de Andrade et al., 2014;
Shibuya et al., 1996). DNAM-1 receptor has been shown to be
fundamental to NK-cell-dependent anti-tumor immunity (Chan
et al., 2014; Gilfillan et al., 2008; Iguchi-Manaka et al., 2008;
Lakshmikanth et al., 2009), and its role in other pathologies
such as autoimmune disease (Huang et al., 2011) and infections
(Cella et al., 2010) is also starting to emerge. Although DNAM-1 is
homogeneously expressed on all T lymphocytes, this receptor is
only expressed on approximately half of mouse splenic NK cells
(Nabekura et al., 2014; Seth et al., 2009). Notably, the maturation
status and phenotype of these two populations of NK cells wereCell Reports 11, 85–97, April 7, 2015 ª2015 The Authors 85
Figure 1. DNAM-1 Expression Identifies NK
Cells with Distinct Cytokine-Secretion
Profiles
(A) 51Cr killing assay involving YAC-1 or RMAs
targets incubated 4 hr at the indicated effector:
target ratio with DNAM-1 or DNAM-1+ NK cells
freshly purified from the spleen of WT mice, naive,
or primed for 24 hr with Poly I:C.
(B) Intracellular IFN-g was analyzed in DNAM-1
and DNAM-1+ fractions of purified spleen NK cells
after stimulation with IL-12 (50 pg/ml) and IL-18
(50 ng/ml). The representative FACS plot (left) and
the mean ± SD of triplicate wells (right) are shown.
(C and D) Representative FACS plot showing the
intracellular IFN-g content (C) and graph showing
the concentrations of the indicated cytokines in
the culture supernatants (D) of purified DNAM-1
and DNAM-1+ NK cells stimulated with the indi-
cated dose of IL-12 and IL-18 (50 ng/ml) for 24 hr.
(E) The concentrations of the indicated cytokines
were analyzed in the supernatants of Rag1/
DNAM-1 and DNAM-1+ NK cells stimulated or
not with IL-12 (25 pg/ml) and IL-18 (50 ng/ml) for
24 hr.
(F) CD11b, CD11b+KLRG1, and CD11b+
KLRG1+ NK cell subsets were sorted into
DNAM-1 and DNAM-1+ NK cells, and the con-
centrations of the indicated cytokines were
analyzed in their culture supernatants after 24 hr
in the presence of IL-12 (25 pg/ml) and IL-18
(50 ng/ml).
(A–F) Mean ± SD from triplicate wells; represen-
tative experiments of at least three independent
experiments. *p < 0.05; **p < 0.01; ***p < 0.001;
Student’s t test.reported to be similar, but until now, the origin and the functional
role of DNAM-1 and DNAM-1+ NK cells have been neglected.
Here, we demonstrate that DNAM-1 and DNAM-1+ NK cells
possess distinct gene-expression profiles and functions. In addi-
tion, we provide evidence through the analysis of NK cell devel-
opment that DNAM-1NK cells develop from DNAM-1+ NK cells
independently of any known NK cell maturation scheme. Collec-
tively, our data reveal the existence of a functional program of NK
cell differentiation based on DNAM-1 expression.
RESULTS
DNAM-1 Expression Identifies NK Cells with Distinct
Cytokine Secretion Profiles
Although the role of DNAM-1 receptor has been thoroughly
investigated in tumor and infectious diseasemodels (de Andrade
et al., 2014), the biology of DNAM-1+ and DNAM-1NK cell pop-86 Cell Reports 11, 85–97, April 7, 2015 ª2015 The Authorsulations remains poorly characterized. To
address this question, we first investi-
gated the killing capacities of both sub-
sets in classical 51Cr assays. We purified
DNAM-1+ and DNAM-1 NK cells from
naive mice or primed in vivo with Poly
I:C and found that the lysis of NKG2D-dependent targets YAC-1 and missing-self targets RMAs were
similar between naive or primed DNAM-1 and DNAM-1+ NK
cells (Figure 1A). We next analyzed the intracellular production
of IFN-g by purified spleen NK cells after in vitro stimulation
with IL-12 (50 pg/ml) and IL-18 (50 ng/ml). Surprisingly, we found
that DNAM-1+ NK cells produced significantly higher amounts
of IFN-g than DNAM-1 NK cells (Figure 1B). To confirm this
result, we next stimulated purified DNAM-1 and DNAM-1+ NK
cells with different doses of IL-12 (10–200 pg/ml) and IL-18
(50 ng/ml). Regardless of the dose tested, DNAM-1+ NK cells
contained higher intracellular levels of IFN-g than DNAM-1
NK cells (Figure 1C). We then performed a more-extensive
screen of the cytokines and chemokines produced in the super-
natants of DNAM-1 and DNAM-1+ NK cells stimulated with
IL-12 and IL-18. Critically, we found that the secretion profile
differed between these two NK cell populations. DNAM-1+ NK
cells produced higher levels of IFN-g, IL-6, GM-CSF, and
Figure 2. DNAM-1 Expression Identifies
Pro-inflammatory and Anti-tumor NK Cells
(A) Representative FACS plot showing the intra-
cellular production of IFN-g and the expression of
CD69 on DNAM-1 and DNAM-1+ spleen NK cells
6 hr after in vivo LPS challenge.
(B) Graph showing the fraction of IFN-g+ DNAM-
1 and DNAM-1+ NK cells fromWT mice 6 hr after
LPS challenge. Mean ± SD from groups of five
mice per time point is shown. Representative
experiment of three performed.
(C) Graph showing the fraction of IFN-g+ DNAM-
1 and DNAM-1+ NK cells 12 hr after Poly I:C
or CpG challenge. Mean ± SD from groups of
five mice. Representative experiment out of two
performed.
(D–G) Rag2/Il2rg/ mice were injected with
PBS (No NKs) or with the indicated numbers of
DNAM-1 and DNAM-1+ NK cells. Five days later,
peripheral blood NK cell reconstitution was
analyzed andmice challengedwith a lethal dose of
LPS i.p. (0.5 mg/30 g mouse; D and E), with
B16F10 melanoma cells (5 3 104 i.v.; F) or RMAs
lymphoma (5 3 103 i.v.; G). Representative
experiment of two using groups of five to tenmice.
(D and E) The survival wasmonitored over time (D),
and the levels of IFN-g, IL-6, and MIP-1a and b
were quantified in the serum 12 hr after LPS
challenge (E). Lungs (F) or liver (G) were collected
14 days after tumor injection, and the mean
number metastases ± SEM are shown for each
group of mice (crossbar) and individual mice rep-
resented by each symbol.
*p < 0.05; **p < 0.01; ***p < 0.001; Mann-Whitney
test (B, C, E, F, and G) and Mantel-Cox test (D).CCL5 whereas DNAM-1 NK cells produced higher amounts of
MIP1a and MIP1b chemokines (Figure 1D). These distinct cyto-
kine secretion profiles were also observed in culture of DNAM-1
and DNAM-1+ NK cells stimulated with other cytokine cocktails
(Figure S1). Similar results were obtained with DNAM-1+ and
DNAM-1 NK cells purified from Rag1/, TCRd/, or CD3ε/
mice (Figures 1E and S1), excluding any role for T cell contami-
nants (Stewart et al., 2007).
Consistent with previous reports (Nabekura et al., 2014; Seth
et al., 2009), we observed that DNAM-1+ and DNAM-1 NK cells
have a classical NK cell phenotype and express similar matu-
ration markers (Figure S1). Yet, to exclude the influence of
previously defined maturation markers, we assessed cytokine
secretion in response to IL-12 and IL-18 stimulation from
CD11b, CD11b+KLRG1, and CD11b+KLRG1+ DNAM-1 and
DNAM-1+ NK cell subsets (Figure 1F). Although the secretionCell Reports 11, 8of some cytokines such as GM-CSF or
MIP1a and b were specific to distinct
maturation stages, the profile of cytokine
secretion of DNAM-1+ and DNAM-1 NK
cells was consistent throughout NK cell
maturation as defined by these subsets
(Figure 1F). Collectively, these results
demonstrate that DNAM-1 expressionallows a new functional separation of NK cells independently
of the previously defined maturation markers.
DNAM-1 Expression Identifies Pro-inflammatory and
Anti-tumor NK Cells
To gain more insight into the functional role of DNAM-1 and
DNAM-1+ NK cell subsets in vivo, we next analyzed DNAM-1
and DNAM-1+ NK cell responses during TLR-ligand-driven
inflammation. After lipopolysaccharide (LPS) injection, we
detected a significantly higher percentage of IFN-g-producing
cells in the DNAM-1+ versus DNAM-1 fraction of NK
cells, although both populations expressed similar levels of
CD69 activation marker (Figures 2A and 2B). Similar observa-
tions were made using other TLR ligands. Twelve hours after
injecting Poly I:C (TLR3 agonist) or CpG DNA (TLR9 agonist),
we observed that DNAM-1+ NK cells contained a higher5–97, April 7, 2015 ª2015 The Authors 87
fraction of IFN-g-producing cells than DNAM-1 NK cells
(Figure 2C).
To better appreciate the pathophysiological functions of
DNAM-1 and DNAM-1+ NK cells in vivo, we transferred purified
DNAM-1 or DNAM-1+ NK cells into Rag2/Il2rg/ mice and
analyzed the endotoxicosis shock syndrome induced by chal-
lenge with a high dose of LPS (Anthony et al., 2010). After
LPS challenge, mice reconstituted with 2 3 105 or 5 3 105
DNAM-1+ NK cells succumbed significantly faster than mice re-
constituted with 5 3 105 DNAM-1 NK cells, whereas non-re-
constituted mice all survived LPS injection (Figures 2D and S2).
Twelve hours after LPS stimulation, serum levels of IFN-g were
significantly higher in mice transferred with DNAM-1+ NK cells
than in mice transferred with DNAM-1 NK cells (Figure 2E).
Mice that did not receive any NK cells had undetectable IFN-g
production in response to LPS. By contrast, all the different
groups of mice had similar levels of non-NK-cell-specific cyto-
kines (Figure 2E). Similar results were obtained using DT-treated
Nkp46iCreR26RDTR, which allows the conditional ablation of NK
cells (Walzer et al., 2007), reconstituted with purified DNAM-1
or DNAM-1+ NK cells (Figure S2).
To extend our knowledge of the anti-tumor functions of
distinct NK cell subsets in vivo, we transferredDNAM-1+NK cells
and DNAM-1NK cells into Rag2/Il2rg/mice that were sub-
sequently challenged with the highly metastatic B16F10 mela-
noma cell line. We found that DNAM-1+ NK cells had superior
anti-metastatic functions to DNAM-1 NK cells. Even low
numbers of DNAM-1+ NK cells were sufficient to clear most if
not all B16F10 metastases, whereas more than 100 metastases
were still present on the lungs ofmice injectedwith DNAM-1NK
cells (Figures 2F and S2). Given that host DNAM-1 is critical
to the suppression of B16F10 lung metastases (Gilfillan et al.,
2008), this result was not unexpected. To confirm these results,
we assessed the anti-tumor functions of DNAM-1+ and
DNAM-1 NK cells using survival (i.p.) and hepatic metastasis
(i.v.) models of RMAs, which expresses CD155 but is cleared
equivalently by WT and Cd226/ (DNAM-1-deficient) mice
(Figure S2). We found that purified DNAM-1+ NK cells were
more effective at controlling RMAs tumor growth and experi-
mental metastasis than DNAM-1 NK cells when transferred
into lymphocyte-deficient Rag2/Il2rg/ mice (Figures 2G
and S2). Collectively, these results demonstrate that DNAM-1+
NK cells are critical effector cells during TLR-ligand-driven
inflammation and tumor suppression in vivo.
DNAM-1+ NK Cell Functions Do Not Depend on DNAM-1
and CD155 Interactions
Recent reports indicate that the differential binding of CD96,
T cell receptor with Ig and ITIM domains (TIGIT), and DNAM-1
to CD155 impacts on NK cell function (Chan et al., 2014; Staniet-
sky et al., 2013). To determine whether increased CD96 and
TIGIT signaling in the absence of DNAM-1 may account for the
differences observed between DNAM-1 and DNAM-1+ NK
cells, we sorted DNAM-1+ and DNAM-1 NK cell populations
from Tigit/ and Cd96/ mice. Upon cytokine stimulation,
DNAM-1+ NK cells produced higher levels of inflammatory cyto-
kines, regardless of the presence or absence of TIGIT and CD96
(Figures 3A and 3B). We next tried to understand the role of88 Cell Reports 11, 85–97, April 7, 2015 ª2015 The AuthorsDNAM-1 and CD155 interactions in the differential functions of
DNAM-1 and DNAM-1+ NK cells. DNAM-1 and DNAM-1+
NK cells were stimulated in the presence or absence of anti-
DNAM-1 mAb (480.1; 10 mg/ml; Chan et al., 2014) to assess
the functional role of DNAM-1 in the cytokine secretion by
DNAM-1 and DNAM-1+ NK cells. Surprisingly, DNAM-1
blockade did not alter the profile of cytokine production by
DNAM-1+ and DNAM-1 NK cells (Figure 3C). Similar results
were obtained when DNAM-1+ and DNAM-1 NK cells
were stimulated in the presence of anti-CD155 mAb (4.24.3;
10 mg/ml; Chan et al., 2014) or when CD155/ NK cells were
used to block the interaction of DNAM-1 with its major ligand
CD155 (Figures 3C and 3D). These results suggest that the func-
tional differences between DNAM-1 and DNAM-1+ NK cells are
not a direct consequence of co-stimulatory signals provided
by DNAM-1 engagement but may rather result from genetic
differences in these populations.
DNAM-1 Expression Is Associated with a Distinct
Gene-Expression Profile
Therefore, to better understand the origin of the functional differ-
ences between DNAM-1 and DNAM-1+ NK cell subsets, we
analyzed their gene-expression patterns by microarray profiling.
A total of 561 and 305 genes were significantly over- and under-
expressed in DNAM-1+ NK cells compared to DNAM-1NK cells
(corrected t test p < 0.05), demonstrating that DNAM-1+ and
DNAM-1 NK cells have distinct gene profiles (Figures 4A, 4B,
and S3). These belonged to several functional families including
transcription factors, cytokines and chemokines, cell cycle,
adhesion molecules, and NK cell receptors (NKRs). DNAM-1
NK cells mainly overexpressed genes related to NKR signaling
such as Klra family genes Cd247, Lat2, Zap70, and Prk (Fig-
ure 4C). Molecular network analysis revealed that NFkB and
PKC networks were the two main molecular networks upregu-
lated in DNAM-1 NK cells (Figure S4). IL-21 and TNF-a were
among the top five transcriptional regulators associated with
the observed gene-expression changes in DNAM-1 NK cells
(Figure S4). DNAM-1+ NK cells expressed higher levels of cyto-
kine-related genes, consistent with their pro-inflammatory pro-
file (Figure 4C). Overall DNAM-1+ NK cells appeared to display
a more-activated phenotype than their DNAM-1 counterparts.
DNAM-1 Expression Is Associated with a More-Active
IL-15 Receptor Pathway
Molecular network analysis revealed that E2F and cytokine-
signaling networks were the two main molecular networks upre-
gulated in DNAM-1+ NK cells (Figures 5A and S4). Interestingly, a
number of genes found upregulated in these two networks are
directly linked to the common IL-2- and IL-15-receptor-signaling
pathway. The signaling through this receptor is pivotal for the
maturation and the acquisition of effector functions of NK cells
(Huntington et al., 2007a). Differences in IL-15 receptor signaling
may explain the functional division between DNAM-1+ and
DNAM-1 NK cells. To confirm this hypothesis, we analyzed
the phosphorylation of key transduction molecules involved in
IL-15-receptor-signaling pathways. We observed higher levels
of phosphorylated JAK1 and STAT5A/B upon IL-15 stimulation
of DNAM-1+ NK cells, compared to the IL-15 response in
Figure 3. DNAM-1 and DNAM-1+ NK Cell Functions Do Not Depend on DNAM-1 and CD155 Interactions
(A and B) FACS-sorted DNAM-1 and DNAM-1+ NK cells from WT, Tigit/, and Cd96/ mice were stimulated with IL-12 (25 pg/ml) and IL-18 (50 ng/ml). The
representative FACS plot showing the intracellular IFN-g content (A) and themean ± SD concentration of the indicated cytokines from triplicate wells (B) from one
representative experiment out of three are shown.
(C) FACS-sorted DNAM-1 and DNAM-1+ NK cells were stimulated with IL-12 (25 pg/ml) and IL-18 (50 ng/ml) in the presence of control Ig (Ctrl Ig), anti-CD155, or
anti-DNAM-1. The mean ± SD from triplicate wells from one representative experiment of three independent experiments is shown.
(D) Representative FACS plot showing the intracellular IFN-g content (left) and graph showing the concentrations of the indicated cytokines in the culture
supernatants (right) of purified Cd155/ andWT DNAM-1 and DNAM-1+ NK cells stimulated with IL-12 and IL-18 for 24 hr. The mean ± SD from triplicate wells
from one representative experiment of three independent experiments is shown.
n.s., p > 0.05; *p < 0.05; **p < 0.01; Student’s t test.DNAM-1 NK cells (Figures 5B and S5). In addition, higher levels
of phosphorylated MEK1/2 were detected in DNAM-1+ NK
cells upon IL-15 stimulation, demonstrating that the IL-15-recep-
tor-mediated MAPK-signaling pathway is also enhanced in
DNAM-1+ NK cells (Figure 5B). Collectively, these results
demonstrate that DNAM-1+ NK cells are characterized by
increased IL-15 receptor signaling.
Recent studies indicate the existence of a positive feedback
loop between IL-15 signaling and the serine threonine kinase
mTOR (mammalian target of rapamycin) (Marc¸ais et al., 2014).
IL-15-mediated activation of mTOR was shown to stimulate
NK cell metabolism to increase IL-15 receptor expression
and was required for IL-15-dependent effector functions. Upon
IL-15 stimulation, we detected higher level of phosphorylation
of mTORC1 downstream targets rsp6 (ribosomal protein S5) in
DNAM-1+ NK cells (Figure 5B). However, the levels of phosphor-
ylation of mTORC2 downstream target Akt1 (Ser437) weresimilar in both subsets (Figure S5). In addition, we could not
detect critical differences in the metabolic activity of DNAM-1
and DNAM-1+ NK cells using seahorse technology and found
that the oxygen consumption rate (OCR) and extracellular acid-
ification rate (ECAR) were not significantly different between
both subsets (Figure S5).
DNAM-1 Expression Identifies NK Cells with Distinct
Proliferative Response
IL-15 receptor is critically involved in NK cell proliferation, andwe
found that a number of genes related to E2F network involved in
cell cycle, cell death, and survival were upregulated in DNAM-1+
NK cells (Figures 5A, S3, and S4). These results prompted us to
investigate the proliferative response of DNAM-1 andDNAM-1+
NK cells. Freshly sorted DNAM-1 and DNAM-1+ NK cells were
labeled with Cell Trace Violet (CTV) and cultured in vitro with IL-2
or IL-15. We observed that DNAM-1+ NK cells proliferated moreCell Reports 11, 85–97, April 7, 2015 ª2015 The Authors 89
Figure 4. DNAM-1 Expression Is Associated with a Distinct Gene-Expression Profile
(A) Heatmap and unsupervised hierarchical clustering of DNAM-1+ and DNAM-1 NK cells genes (six independent samples are shown for each population).
(B) Comparison plots of normalized expression values. Numbers indicate genes whose expression differed by more than 1.5-fold between DNAM-1+ and
DNAM-1 NK cells. Differentially expressed genes are highlighted in gray (p < 0.05 unpaired t test).
(C) Heatmap of genes related to transcription factors, cell cycle, cytokines and chemokines, cellular adhesion, and NK cell receptor signaling differentially
expressed (p < 0.05 unpaired t test) between DNAM-1+ and DNAM-1 NK cells (six independent samples from each population are shown).vigorously than DNAM-1NK cells in response to IL-2 and IL-15,
confirming the enhanced sensitivity of DNAM-1+ NK cells for
these two cytokines (Figure 6A). To investigate NK cell prolifera-
tion in vivo, we transferred DNAM-1 and DNAM-1+ NK cells
from adult mice into Rag2/Il2rg/ mice. Analysis of NK cell
reconstitution revealed that DNAM-1+ NK cells have higher
homeostatic expansion capacities than DNAM-1 NK cells.
Indeed, up to 4 weeks after injection, we recovered higher NK
cell numbers and percentages in Rag2/Il2rg/ mice trans-
ferred with DNAM-1+ NK cells than in mice transferred with
DNAM-1 NK cells (Figures 6B and S6). Analysis of NK cell pro-
liferation 5 days after cell transfer into Rag2/Il2rg/ mice
through CTV dilution revealed that DNAM-1+ NK cells undergo
higher number of divisions than DNAM-1 NK cells (Figures 6C
and S6). We confirmed the superior proliferative potential of
DNAM-1+ NK cells over DNAM-1 NK cells by injecting both
subsets simultaneously into Rag2/Il2rg/ (Figure 6D).
The depletion of Tregs was previously shown to induce the
production of IL-2 by conventional T cells, leading to themassive
expansion of NK cells (Gasteiger et al., 2013). We took advan-
tage of the Foxp3DTR mice to analyze the IL-2-induced prolifera-
tion of DNAM-1 and DNAM-1+ NK cells in vivo. The depletion of
Tregs with DT for 5 days increased the fraction of Ki67+-prolifer-
ating cells in both DNAM-1 and DNAM-1+ NK cell populations
compared to PBS treatment (Figure 6E). However, a significantly
higher fraction of Ki67+-proliferating cells was detected in the90 Cell Reports 11, 85–97, April 7, 2015 ª2015 The AuthorsDNAM-1+ fraction of NK cells (Figures 6E and 6F). As a conse-
quence, the numbers and the percentages of DNAM-1+ NK cells
were selectively enriched in the spleen of mice treated for 5 days
with DT as compared to PBS-treated mice (Figures 6F and 6G).
Together, these results indicate that DNAM-1 expression iden-
tifies NK cells with a greater ability to proliferate under lympho-
penic conditions or following cytokine stimulation.
DNAM-1 NK Cells Arise from DNAM-1+ NK Cells
through an Alternative Maturation Program
Given the critical differences between DNAM-1 and DNAM-1+
NK cells, we wanted to address the developmental origin
of these two NK cell populations. We first purified splenic
DNAM-1 and DNAM-1+ NK cells from adult mice that were
subsequently transferred into Rag2/Il2rg/ mice. Analysis
of DNAM-1 expression 2–8 weeks after injection revealed that
DNAM-1 NK cells have a stable phenotype in vivo (Figure 7A).
By contrast, we saw a progressive emergence of DNAM-1
NK cells over time in the Rag2/Il2rg/ mice injected with
DNAM-1+ NK cells (Figure 7A). Similar results were obtained
when purified DNAM-1 and DNAM-1+ NK cells were cultured
in vitro with IL-2 (Figure S7).
We next analyzed the relationship between these two popula-
tions during the neonatal emergence of NK cells. Interestingly,
we observed that most of the NK cells were DNAM-1+
10 days after birth, with the DNAM-1 population being almost
Figure 5. DNAM-1 Expression Is Associated
with a More-Active IL-15 Receptor Pathway
(A) Molecular network analysis of DNAM-1+ upre-
gulated genes. Cell-cycle and cytokine-signaling
networks were generated from the microarray
analysis of genes differentially expressed between
DNAM-1+ and DNAM-1 NK cells. Red represents
upregulation, and green represents down-
regulation. Numbers indicate fold change of gene
expression. E2F network (upper diagram) shows
that 28 genes related to cell cycle, cell death and
survival, cellular assembly, and organization were
upregulated in DNAM-1+ NK cells. Cytokine-
signaling network (lower diagram) shows that
27 focus molecules involved in cell-mediated
immune response, cellular development, cellular
functions, and maintenance were upregulated in
DNAM-1+ NK cells.
(B) Purified DNAM-1 or DNAM-1+ NK cells were
stimulated with IL-15 (5 ng/ml) for 0, 15, 30, 60, or
120 min. Western blots using antibodies directed
against the indicated total and phosphorylated (p)
proteins are shown. Representative experiment
out of two performed.undetectable (Figure 7B). During the first 60 days after birth, the
percentage and the number of DNAM-1 NK cells progressively
increased to reach similar number and percentages to the
DNAM-1+ population (Figures 7B–7D). We observed concomi-
tant changes in CD11b immature and mature CD11b+CD27+
and CD11b+CD27NK cell subsets (Figure 7C). However,
DNAM-1 NK cell development was independent of CD27/
CD11b NK cell maturation scheme because immature and
mature NK cells subsets were similarly represented in DNAM-1
and DNAM-1+ NK cells throughout NK cell neonatal develop-
ment (Figure S7). We next used the Nkp46iCreR26RDTR mice to
analyze in adult mice the kinetics of DNAM-1 and DNAM-1+
NK cell subset recovery after diphtheria toxin (DT)-induced NK
cell depletion. As observed for neonatal NK cells, most of the
newly generated NK cells were DNAM-1+ whereas DNAM-1
developed later (Figure 7E). These results suggest that
DNAM-1 NK cells develop from DNAM-1+ NK cells rather
than from separate precursors. To confirm this assumption,
we purified DNAM-1+ NK cells from 10-day-old WT mice
and transferred them into Rag2/Il2rg/ mice. We observed
a progressive differentiation of the transferred immature
DNAM-1+ NK cells into mature DNAM-1+ and DNAM-1 NK
cells (Figure 7F).
To determine whether the differentiation of DNAM-1+ NK
cells into DNAM-1 is restricted to a specific NK cell stage,
we next sorted immature CD11b, mature CD11b+KLRG1,
and terminally differentiated CD11b+KLRG1+ NK cells into
DNAM-1+ and DNAM-1 populations and transferred them into
Rag2/Il2rg/ mice. Interestingly, we observed that DNAM-
1+ could differentiate into DNAM-1 NK cells at any stage of
maturation (Figure 7G). By contrast, regardless of the maturation
stage, DNAM-1 retained their DNAM-1 phenotype, confirming
the inability of these cells to re-express DNAM-1 (Figure 7G).
These results confirm that DNAM-1 allows the identification of
two splenic NK cell subsets independently of the knownmatura-
tion markers: DNAM-1+ and DNAM-1 NK cells.DISCUSSION
Here, we demonstrated through the analysis of NK cell develop-
ment, transcriptional profiling, and functional studies that the
activating receptor DNAM-1 regulates an alternative program
of differentiation to generate two distinct NK cell functional sub-
sets: DNAM-1+ and DNAM-1 NK cells. DNAM-1+ NK cells had
enriched expression of IL-15-signaling-related genes, prolifer-
ated vigorously, produced high levels of effector cytokines,
and represented critical effector cells during inflammatory and
anti-tumor reactions. In contrast, DNAM-1 NK cells had a
greater expression of NKR-related genes and were higher pro-
ducers of MIP1 chemokines. Finally, we provided strong
evidence that DNAM-1 NK cells represent a stable subset
that differentiates from DNAM-1+ NK cells independently of the
classical NK cell maturation pathway. Collectively, our data
reveal the existence of a new functional program of NK cell differ-
entiation based on DNAM-1 expression.
Defective Ly49H+ NK cell memory responses to MCMV were
recently described in the absence of DNAM-1. DNAM-1 ligands
were induced during MCMV infection, and the engagement of
DNAM-1 on NK cells was required for optimal MCMV clearance.
Because experiments conducted in this study were performed
using gene-targeted mice and blocking antibodies, the intrinsic
functions and properties of DNAM-1+ and DNAM-1 NK cells
were not investigated (Nabekura et al., 2014). By contrast, in
our study, we provide strong evidence that DNAM-1 and
DNAM-1+ NK cells represent distinct NK cell subsets with diver-
gent functions. Nabekura et al. (2014) demonstrated that Ly49H+
and DNAM-1+ NK cells lose DNAM-1 expression during the
course of infection. However, because approximately half of
mouse NK cells are DNAM-1 in steady state (uninfected),
regardless of the expression of Ly49H (Seth et al., 2009), the rela-
tionship between DNAM-1 and DNAM-1+ NK cells was unclear.
In our work, through the analysis of NK cell development and
adoptive transfer experiments using sorted neonatal or adultCell Reports 11, 85–97, April 7, 2015 ª2015 The Authors 91
Figure 6. DNAM-1 Expression Identifies NK Cells with Distinct Proliferative Capacities
(A) Representative FACS histograms showing the proliferation of Cell-Trace-Violet-labeled DNAM-1 (white histogram) or DNAM-1+ NK cells (gray histogram)
stimulated with the indicated concentration of IL-2 or IL-15 for 5 days. Representative experiment out of three performed.
(B) Box plots showing the total number of spleen NK cells recovered 1, 2, or 4 weeks after DNAM-1 or DNAM-1+ NK cell injection intoRag2/Il2rg/mice. Data
are pooled from at least two independent experiments involving groups of six to ten mice per time point.
(C) Representative FACS plots showing the total percentage among spleen cells (upper panel) and the percentage of divided NK1.1+CD3 NK cells (lower panel)
5 days after injection into Rag2/Il2rg/ mice. Representative experiment of three performed.
(D) Cell-Trace-Violet-labeled DNAM-1+ and DNAM-1 NK cells were sorted from WT and Nkp46iCreR26ReYFP, respectively, and transferred simultaneously into
Rag2/Il2rg/ mice. Representative FACS plots showing the total percentage (central panel) and the percentage of divided DNAM-1 (YFP+) and DNAM-1+
(YFP) NK cells (lower panel) 5 days after injection. Representative experiment out of two performed.
(E–G) The expansion of DNAM-1 and DNAM-1+ NK cells was analyzed in BALB/c Foxp3DTR mice 5 days after treatment with DT or PBS vehicle. (E and F)
Representative density plots (E) and graphs (F) showing the percentage of Ki67+ cells, the percentage among spleen cells, and the total number of spleen
DNAM-1 and DNAM-1+ fractions of NK cells after Treg depletion or not. (G) Graph showing the percentage of NK cells expressing DNAM-1 after Treg depletion
or not. (F and G) Mean ± SD from a representative experiment of two independent experiments involving groups of five mice.
(B, F, and G) **p < 0.01; ***p < 0.001; Mann-Whitney test.NK cells, we demonstrated that DNAM-1NK cells develop from
DNAM-1+ NK cells. Interestingly, the differentiation of DNAM-1+
into DNAM-1 NK cells was not restricted to a particular subset
of DNAM-1+ NK cells because both immature CD11b and
mature NK cells progressively differentiated into DNAM-1 NK
cells when transferred into lymphopenic hosts. Surprisingly,
the results of Nakebura and colleagues (Nabekura et al., 2014)
suggest that DNAM-1 Ly49H+ NK cells are also plastic and
can change their DNAM-1 phenotype during the course of infec-
tion. However, in contrast with Nabekura et al., our experiments
demonstrate that DNAM-1 NK cells are not plastic and repre-92 Cell Reports 11, 85–97, April 7, 2015 ª2015 The Authorssent a final stage of NK cell differentiation. Perhaps DNAM-1
may be acquired by membrane exchange (trogocytosis)
between NK cells and APCs that can express DNAM-1 (Joly
and Hudrisier, 2003). Another possibility is contamination by
DNAM-1+ NK cells in the DNAM-1 NK cell fraction that would
expand during the course of MCMV infection.
The molecular determinants controlling the differentiation of
DNAM-1+ into DNAM-1 NK cells remain to be fully understood.
One possibility is that DNAM-1 interaction with CD155 might
down-modulate the expression of DNAM-1. We analyzed
DNAM-1 expression in Cd155/ mice and found that the ratio
Figure 7. DNAM-1 NK Cells Differentiate from DNAM-1+ NK Cells
(A) Purified DNAM-1 or DNAM-1+ NK cells were transferred into Rag2/Il2rg/ mice. Representative histogram (left panel) or graph (right panel) showing
DNAM-1 expression on spleen NK cells isolated 2–8 weeks after injection.
(B–D) Representative density plots and graphs showing the percentage (B and C) and number (D) of the indicated WT spleen NK cell subsets during neonatal
development. Representative experiment of two involving groups of three to ten mice per time point.
(E) The percentage of DNAM-1 spleen NK cells was analyzed in Nkp46iCreR26RDTR or Nkp46WTR26RDTR mice after DT injection. Experiment involving groups of
four to six mice per time point.
(F) Purified spleen DNAM-1+ NK cells from 10-day-old WTmice were transferred into Rag2/Il2rg/mice, and DNAM-1 expression was analyzed on spleen NK
cells 1–6 weeks after injection. Representative histograms showing the expression of DNAM-1 (black histogram) compared to isotype control staining (open
histogram) from experiments involving five to ten mice per time point are shown.
(G) CD11b, CD11b+KLRG1, and CD11b+KLRG1+ NK cells were sorted into DNAM-1+ and DNAM-1 NK cell populations and transferred into Rag2/Il2rg/
mice. Three weeks after transfer, DNAM-1 expression was analyzed on spleen NK1.1+CD3 NK cells. A representative experiment of two involving five mice per
time point is shown.
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of DNAM-1+ and DNAM-1 NK cells was consistent with WT
mice, demonstrating that CD155 is not involved in the loss of
DNAM-1 expression (Figure S7). As already demonstrated by
other groups (Seth et al., 2009), we observed that mRNAs for
DNAM-1 were almost absent in DNAM-1 NK cells compared
to DNAM-1+. This suggests there must be a strong repression
of the DNAM-1 gene occurring in DNAM-1NK cells that is inde-
pendent of ligand binding. NK cell differentiation is often pre-
ceded by a proliferation stage, and blocking NK cell proliferation
also blocks NK cell maturation (Marc¸ais et al., 2014). Analysis of
DNAM-1 differentiation in vitro during the course of NK cell pro-
liferation revealed that the emergence of DNAM-1 NK cells was
mainly confined toNK cells that had undergone several rounds of
division (Figure S7). This raises the question as to whether
DNAM-1 NK cells may differentiate from DNAM-1+ NK cells
upon the stochastic loss of DNAM-1 expression during NK cell
proliferation. IL-15 plays a pivotal role in the progression of
immature NK cells toward more-mature NK cell stages (Hunting-
ton et al., 2009; Vosshenrich et al., 2005). For example, a reduc-
tion in IL-15 signaling blunts the development of NK cells at the
CD11b stage and, conversely, increased IL-15 concentrations
induce the accumulation of KLRG1+ NK cells (Huntington et al.,
2007b, c; Lee et al., 2011). IL-15 receptor downstream signals
may control the differentiation of DNAM-1 NK cells because
DNAM-1 NK cells have less-active IL-15 signaling and IL-15
stimulates DNAM-1 expression.
Transcriptional analysis of DNAM-1 and DNAM-1+ NK cells
revealed that these two subsets have distinct gene signatures.
Interestingly, a number of genes overexpressed in DNAM-1+
NK cells were directly related to IL-15 signaling. In accordance
with the mitogenic and anti-apoptotic properties of this cytokine
(Fehniger et al., 2001; Gilmour et al., 2001; Huntington et al.,
2007c), numbers of cell-cycle- and survival-related genes were
also specifically increased in DNAM-1+ NK cells. Analysis of IL-
15 signaling confirmed thatDNAM-1+NKcells haveamoreactive
IL-15-signaling pathway with higher levels of JAK1 and STAT5
phosphorylation upon IL-15 stimulation. Given the pivotal role
played by this cytokine in controlling diverse aspects of NK cell
biology, such as proliferation and acquisition of effector func-
tions, it is likely that such differences in IL-15 reactivity account
for the divergent functions of DNAM-1 and DNAM-1+ NK cells.
The molecular basis for enhanced IL-15 signaling remains to be
fully understood. Indeed, we could not detect any substantial dif-
ferences in the cell surface expression of IL-15Rb (CD122) and
common gc chain (CD132) between DNAM-1 and DNAM-1+
NKcells, and IL-15-mediatedactivationof thePI3K-Akt-signaling
cascade was similar between these two NK subsets.
DNAM-1 is an adhesion molecule originally shown to control
NK and T cell cytotoxicity upon interaction with its ligands
CD155 and CD112, which are frequently upregulated upon
cellular transformation (Bottino et al., 2003; Shibuya et al.,
1996). This receptor seems to play a broader role than initially
thought in NK cell biology because recent studies indicate that
DNAM-1 also controls immune synapse formation, cytokine
secretion, and memory NK cell differentiation (Chan et al.,
2014; de Andrade et al., 2014; Nabekura et al., 2014; Ramsbot-
tom et al., 2014). In addition to these functions, here, we demon-
strate that DNAM-1 separates NK cells in two functional subsets.94 Cell Reports 11, 85–97, April 7, 2015 ª2015 The AuthorsInterestingly, we found that blocking DNAM-1/ligand interac-
tions during functional assays using Cd155/ NK cells or
anti-CD155 and anti-DNAM-1 mAbs did not alter DNAM-1-
and DNAM-1+-related functions. These results suggest that
DNAM-1 engagement does not directly account for the func-
tional differences between these two NK cell subsets but rather
may be involved in the epigenetic control of DNAM-1+ NK cell
identity. We can speculate that cellular interactions and signals
provided to DNAM-1 and DNAM-1+ NK cells might be different,
ultimately leading to functional divergence. Indeed, DNAM-1
at the cell surface of lymphocytes constantly interacts with its
ligands expressed on DCs (Seth et al., 2011), and the absence
of this receptor has been shown to negatively impact NK cell
and DC crosstalk (Pende et al., 2006; Ramsbottom et al., 2014;
Shibuya et al., 1996). The absence of DNAM-1 on NK cells
may therefore limit their access to homeostatic DC-derived
signals including IL-15 (Lucas et al., 2007). Thus, NK cell/DC
crosstalk defects in the absence of DNAM-1 may underlie the
lower IL-15 reactivity of DNAM-1 NK cells.
DNAM-1+ and DNAM-1 NK cells greatly differed in their
expression of adhesion molecules and their NKR repertoire.
Genes coding for NKR (Ly49D, G, H, and M) and NKR-signaling
molecules (LAT, ZAP70, andPKC)were among themost-upregu-
lated genes in DNAM-1NKcells. These results contrast with the
increased expression of genes related to cytokine signaling in
DNAM-1+ NK cells and suggest that DNAM-1 NK cell reactivity
may be controlled by NKR-derived cellular signals whereas
DNAM-1+ reactivity may be controlled by accessory cell-derived
cytokines. Although this idea is attractive, we could not find clear
evidence demonstrating enhanced NKR reactivity in DNAM-1
NK cells. For example, the in vitro lysis of YAC-1 and RMAs
was similar between DNAM-1 and DNAM-1+ NK cells, demon-
strating equal missing-self and NKG2D-dependent killing. By
contrast, DNAM-1+ NK cells had superior anti-tumor functions
to DNAM-1NK cells in vivo. It will bemost interesting to confirm
the role of these subsets using CD155 tumor cell lines, because
virtually all of the mouse tumor cell lines of solid or hematological
origin express some or significant levels of CD155.
Although mouse and human NK cells exert similar functions
and share some common developmental pathways, their pheno-
type greatly differs between these two species, making transla-
tional discovery difficult (Huntington et al., 2007a). Mouse NK
cells are mainly separated based on their expression of CD11b
and CD27, whereas human NK cells are dichotomized based
on the level of expression of the CD56 adhesion molecule.
CD56bright NK cells proliferate vigorously and produce high
amount of inflammatory mediators in response to exogenous
cytokine stimulation, whereas CD56dim effector functions are
mainly elicited by NKR triggering (Cooper et al., 2001a, b; Fauriat
et al., 2010). DNAM-1+ and DNAM-1 NK cell global gene-
expression profiles and functional attributes suggest these cells
may represent the mouse analogs of human CD56bright and
CD56dim NK cells. Similar to human CD56bright and CD56dim
NK cell subsets (Cooper et al., 2001b), we found increased levels
of DNAM-1+ NK cells in peripheral lymph nodes and in the BM,
whereas DNAM-1 NK cells were more prevalent in the blood
and in the lung. Although most human peripheral blood NK cells
express DNAM-1 (El-Sherbiny et al., 2007), several studies
revealed the presence of a population of NK cells with lower
DNAM-1-receptor expression in cancer patients (Carlsten
et al., 2009; Mamessier et al., 2011; Sanchez-Correa et al.,
2012). Constant ligand exposure was found to support
DNAM-1 down-modulation, and accumulating evidence sug-
gests that loss of DNAM-1 expression is associated with a
decrease in NK cell function (Carlsten et al., 2009; Mamessier
et al., 2011). Until now, it remains unclear whether these NK cells
have a stable phenotype and could represent the equivalent of
mouse DNAM-1 NK cells. A better understanding of the role
of DNAM-1 on NK cell behavior may therefore have future ther-
apeutic application in cancer patients.
EXPERIMENTAL PROCEDURES
Mice
BALB/c and C57BL/6 wild-type mice were obtained from the Walter and Eliza
Hall Institute for Medical Research or ARC Animal Resource Centre. Rag1/,
Rag2/Il2rg/, Cd226/, and Cd96/ have been described (Chan et al.,
2014). Nkp46iCreR26ReYFP and Nkp46iCreR26RDTR mice were kindly provided
by Dr. Eric Vivier (Narni-Mancinelli et al., 2011). Tigit/ mice were provided
by Bristol Myers Squibb. Cd155/ mice were kindly provided by Dr. Yoshimi
Takai (KobeUniversity). BALB/cFoxp3DTRmicewere providedbyDr. Alexander
Rudensky (Kim et al., 2007). All mice were bred and maintained at the QIMR
Berghofer Medical Research Institute and were used at the age of 6–12 weeks.
Group sizes were designed to ensure adequate power for the detection of bio-
logical differences. No mice were excluded on the basis of pre-established
criteria, and no active randomization was applied to experimental groups. The
investigators were not ‘‘blinded’’ to group allocation during the experiment
and/or when assessing the outcome. All experiments were approved by
QIMR Berghofer Medical Research Institute animal ethics committees.
51Cr Cytotoxicity Assays
The B16F10 melanoma cell line, RMAs, and YAC-1 lymphoma cell lines (all
fromAmerican TypeCulture Collection) were grown at 37C in 5%CO2 in com-
plete RPMI medium (e.g., supplemented with 10% FCS [Thermo Scientific],
L-glutamine, nonessential amino acids, sodium pyruvate, HEPES, and peni-
cillin-streptomycin [all GIBCO]). Standard 51Cr cytotoxicity assays were used
to measure the ability of DNAM-1 and DNAM-1+ NK cells to kill targets. NK
cells were added to 51Cr-labeled targets at defined effector-to-target ratios.
After 4 hr at 37C in 5% CO2, supernatants were harvested, and the level
of 51Cr was quantified by a gamma counter (Chan et al., 2010).
Treg and NK Cell Depletion
Tregs were depleted from BALB/c Foxp3DTR mice by successive i.p. injection
of DT (200 ng/30 g of body weight; Merck) at days 0, 2, and 4. Mice were sacri-
ficed at day 5 to analyze the expansion of spleen DNAM-1 and DNAM-1+ NK
cells and depletion of Foxp3+ T cells. NK cells were depleted from Nkp46i-
CreR26RDTR mice by two successive daily injections i.p. of DT (8 ng/g
of body weight; Merck). Littermates Nkp46WTR26RDTR control mice were
included in each experiment. The depletion of retro-orbital sinus blood
NKp46+ NK cells was determined prior to each experiment.
NK Cell Purification and Activation
NK cells were enriched from the spleens of the appropriate strains of mice by
MACS technology (NK cells isolation kit II; Miltenyi Biotec), using an auto-
MACS pro separator (Miltenyi Biotec). Enriched NK cells preparations
were then stained with mAb to NK1.1 (PK136; eBioscience), mAb to TCRb
(H57-597; eBioscience), mAb to CD3 (17A2; eBioscience), mAb to NKp46
(29A1.4; BioLegend), and mAb to DNAM-1 (480.1; BioLegend), and DNAM-
1 or DNAM-1+ NK cells were sorted on a FACSAria II (BD Biosciences). NK
cells were labeled with CTV (Life Technologies) according to the manufac-
turer’s instructions. Freshly purified NK cells were plated in 96-well
U-bottomed plates in complete RMPI medium supplemented with the
indicated concentrations of recombinant human IL-2 (100–1,000 U/ml;Chiron), mouse IL-12 (25–100 pg/ml; eBioscience), mouse IL-15-IL-15Ra
(1–100 ng/ml; eBioscience), and mouse IL-18 (50 ng/ml; R&D Systems). The
production of cytokines was analyzed in the supernatant and in NK cells after
24 hr of culture, whereas the proliferation of NK cells was analyzed after 5 days
of culture. Where indicated, mAb to DNAM-1 (10 mg/ml; 480.1), mAb to CD155
(10 mg/ml; 4.24.3), or irrelevant IgG1 (HRPN; Bio X cell) was added.
TLR Ligand Challenge
LPS (from Escherichia coli strain 0127:B8; Sigma) suspended in PBS was in-
jected i.p. into mice at various doses (0.1 mg and 0.5 mg per 30 g mouse
body weight). TLR3 agonist Poly (I:C) (100 mg; Sigma) and TLR9 agonist
CpGDNA (100 mg; Sigma) were injected i.v. For adoptive transfer experiments,
DNAM-1 or DNAM-1+ NK cells (2–5 3 105) freshly purified from WT
mice were injected via the tail vein of Rag2/Il2rg/ mice or DT-treated
Nkp46iCreR26RDTR mice. The NK cell reconstitution was analyzed 5 days later
and mice were challenged by i.p. injection of LPS (0.5 mg/30 g mouse). Blood
was obtained 12 hr after TLR ligand injection from the retro-orbital sinuses, and
the serumwas used for cytokine analysis. Spleens were obtained frommice at
various time points for analysis of receptor expression and intracellular expres-
sion of IFN-g by NK cells. For survival experiments, mice were checked hourly
for signs of sepsis.
Flow Cytometry and Cytokine Detection
Cells harvested from in vitro cultures or single-cell suspensions from various
organs were incubated for 15 min in Fc-blocking buffer (2.4G2). Cells were
then stained with the appropriate antibodies from eBioscience (mAb to CD3
[17A2], mAb to CD69 [H1.2F3], mAb to NK1.1 [PK136], mAb to TCRb [H57-
597], mAb to Ki67 [SolA15], or mAb to KLRG1 [2F1]) or from BioLegend
(mAb to DNAM-1 [480.1], mAb to CD11b [M1/70], or mAB to NKp46
[29A1.4]). Data were acquired with an LSR II Fortessa (BD Biosciences) and
were analyzed with FlowJo software (TreeStar). All cytokines were detected
by cytometric bead array technology according to the manufacturer’s instruc-
tions (BD Biosciences). For detection of intracellular cytokines, splenocytes
from TLR-ligand-injected mice or in-vitro-activated NK cells were stained,
fixed, and permeabilized with Cytofix/Cytoperm (BD Biosciences) and then
were stained with an anti-IFN-g mAb (XMG1.2; BD Biosciences).
Tumor Assays
DNAM-1 or DNAM-1+ NK cells (2–5 3 105) were injected via the tail vein into
Rag2/Il2rg/ mice. The reconstitution of each mouse by NK cells was
analyzed 5 days later in the peripheral blood by flow cytometry, and mice
were then given an intravenous injection of B16F10 melanoma cells (5 3
104) or RMAs lymphoma cells (5 3 103). Lungs or livers, respectively, were
collected after 14 days, and B16F10 or RMAs tumor nodules were counted
under a dissection microscope (Chan et al., 2010). Survival of mice injected
with the RMAs lymphoma cells i.p. (5 3 102) was monitored.
DNAM-1 and DNAM-1+ NK Cell Homeostasis
Two hundred thousand DNAM-1 or DNAM-1+ NK cells labeled with CTVwere
injected via the tail vein into Rag2/Il2rg/ mice. The proliferation, the per-
centage, the number, and DNAM-1 expression were analyzed on transferred
NK cells in the spleen of each mouse 5 days to 8 weeks after injection. To
analyze the neonatal expansion of DNAM-1 or DNAM-1+ NK cells, 10- to
100-day-old C57BL/6 WT mice were sacrificed and the percentage, the num-
ber, and DNAM-1 expression on spleen NK cells were determined by flow
cytometry. Alternatively, some experiments were conducted on DT-treated
Nkp46iCreR26RDTR mice to analyze DNAM-1 expression during NK cell recov-
ery in adult mice.
Microarray
The total RNA was extracted from purified DNAM-1 or DNAM-1+ NK cells us-
ing RNeasy micro kit (QIAGEN). The integrity and the quantity of the RNA were
evaluated using 2100 Bioanalyzer (Agilent Technologies). Using the Illumina
TotalPrep RNA Amplification Kit (Ambion), 300 ng of RNA were reverse tran-
scribed into cRNA and thereby labeled with biotin-UTP. Hybridization of
1,500 ng of labeled cRNA to the Illumina mouse WG-6 v2.0 Expression Bead-
chip array was followed by washing steps as described in the protocol.Cell Reports 11, 85–97, April 7, 2015 ª2015 The Authors 95
Microarray analysis was performed according to manufacturer’s instructions.
Student’s t test was used to determine differentially expressed genes between
samples. Multiple testing corrections were used to adjust p values derived
from multiple tests.
Molecular Network Analysis
Differentially expressed genes identified from the microarray analysis
comparing DNAM-1+ and DNAM-1 NK cells were used. The molecular
network was algorithmically constructed by Ingenuity Pathway Analysis (IPA)
software (QIAGEN) on the basis of the functional and biological links between
genes. Gene-expression data are overlaid on the network to show up- and
downregulated genes as red and green, respectively.
Seahorse Assay
XF96 cell culture microplates (Seahorse Bioscience) were first coated with
0.1% gelatin for 30 min at 37C before the addition of 2 3 105 DNAM1+/
NK cells in unbuffered glucose-free DMEM. NK cells were stimulated with
glucose (25 mM), oligomycin (1 mM), FCCP (1.5 M) plus pyruvate (1 mM),
and antimycin A (1 mM) plus rotenone (0.1 mM) with ECAR and OCR being
measured every 7 min for 105 min by an XF-96 Extracellular Flux Analyzer
(Seahorse Bioscience).
Western Blot Analysis
Onemillion DNAM-1 or DNAM-1+ NK cells were stimulated in complete RPMI
supplemented with IL-2 (500 U/ml) or IL-15 (5 ng/ml) for 0, 15, 30, or 60 min.
Cells were harvested and lysed in RIPA buffer (300 mM NaCl, 2% IGEPAL
CA-630, 1% deoxycholic acid, 0.2% SDS, and 100 mM Tris-HCl [pH 8.0])
with protease inhibitors (Roche Diagnostics), 1 mM sodium orthovanadate
(Sigma), and 10 mM sodium fluoride. About 30 mg of protein was loaded into
NuPAGE 10% Bis-Tris gels. Western blots were probed with the following an-
tibodies: a-P-STAT5a/b (Tyr694/699; Millipore), a-STAT5a (Zymed) a-P-JAK1
(Tyr1022/1023; Invitrogen), a-JAK1 (HR-785; 1:1,000; Santa Cruz), a-P-Akt1
(Ser473; Cell Signaling Technology), a-P-MEK1/2 (Ser217/221; Cell Signal),
a-P-p42/44 MAPK (Tyr 202/204; Cell Signal), a-P-rsp6 (Ser235/236; Cell Signal),
and a-b-actin-HRP (Santa Cruz Biotechnology). Antibody binding was visual-
ized with horseradish-peroxidase-conjugated secondary antibodies: sheep
anti-rabbit immunoglobulin or sheep anti-mouse immunoglobulin (GE Health-
care) and the enhanced chemiluminescence (ECL) system (Millipore) or
Amersham ECL (GE Healthcare). To re-blot, membranes were first stripped
of antibodies in 0.1 M glycine (pH 2.9).
Statistical Analysis
Statistical analysis was achieved using Graphpad Prism Software. Data were
compared by an unpaired Student’s t test when values followed a Gaussian
distribution with similar variances or with the Mann Whitney test. Differences
in survival were evaluated with a Mantel-Cox test.
ACCESSION NUMBERS
The full microarray data set has been deposited in Gene Expression Omnibus
(GEO) under submission number GSE66281.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and can be found with this
article online at http://dx.doi.org/10.1016/j.celrep.2015.03.006.
AUTHOR CONTRIBUTIONS
All authors contributed to the experiments in thismanuscript. L.M., N.D.H., and
MJ.S. designed the study and wrote the manuscript.
ACKNOWLEDGMENTS
The authors thank Liam Town, Joanne Sutton, and Kate Elder for the care and
maintenance of the mouse colonies. We thank Fiona Amante, Marcela Montes96 Cell Reports 11, 85–97, April 7, 2015 ª2015 The AuthorsDe Oca, Christian Engwerda, and Fares Al-Ejeh for their technical and scienti-
fic help. M.J.S. is supported by a NHMRC Australia Fellowship (628623). L.M.
is supported by the ARC Cancer Research Foundation. D.S.H. was supported
by a NHMRC Career Development Fellowship. The project was supported by
NHMRC program grants (1013667 and 1016647) and project grants (1044392,
1049407, 1066770, and 1057852) and was supported in part by an NHMRC
IRIISS grant 361646 and a Victorian State Government Operational Infrastruc-
ture Scheme grant.
Received: October 15, 2014
Revised: December 31, 2014
Accepted: February 27, 2015
Published: March 26, 2015
REFERENCES
Anthony, D.A., Andrews, D.M., Chow,M., Watt, S.V., House, C., Akira, S., Bird,
P.I., Trapani, J.A., and Smyth, M.J. (2010). A role for granzyme M in TLR4-
driven inflammation and endotoxicosis. J. Immunol. 185, 1794–1803.
Bottino, C., Castriconi, R., Pende, D., Rivera, P., Nanni, M., Carnemolla, B.,
Cantoni, C., Grassi, J., Marcenaro, S., Reymond, N., et al. (2003). Identification
of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human
DNAM-1 (CD226) activating molecule. J. Exp. Med. 198, 557–567.
Carlsten, M., Norell, H., Bryceson, Y.T., Poschke, I., Schedvins, K., Ljunggren,
H.G., Kiessling, R., and Malmberg, K.J. (2009). Primary human tumor cells
expressing CD155 impair tumor targeting by down-regulating DNAM-1 on
NK cells. J. Immunol. 183, 4921–4930.
Cella, M., Presti, R., Vermi, W., Lavender, K., Turnbull, E., Ochsenbauer-Jam-
bor, C., Kappes, J.C., Ferrari, G., Kessels, L., Williams, I., et al.; CHAVI Clinical
Core B; NIAID Center for HIV/AIDS Vaccine Immunology (2010). Loss of
DNAM-1 contributes to CD8+ T-cell exhaustion in chronic HIV-1 infection.
Eur. J. Immunol. 40, 949–954.
Chan, C.J., Andrews, D.M.,McLaughlin, N.M., Yagita, H., Gilfillan, S., Colonna,
M., and Smyth, M.J. (2010). DNAM-1/CD155 interactions promote cytokine
and NK cell-mediated suppression of poorly immunogenic melanoma metas-
tases. J. Immunol. 184, 902–911.
Chan, C.J., Martinet, L., Gilfillan, S., Souza-Fonseca-Guimaraes, F., Chow,
M.T., Town, L., Ritchie, D.S., Colonna, M., Andrews, D.M., and Smyth, M.J.
(2014). The receptors CD96 and CD226 oppose each other in the regulation
of natural killer cell functions. Nat. Immunol. 15, 431–438.
Chiossone, L., Chaix, J., Fuseri, N., Roth, C., Vivier, E., and Walzer, T. (2009).
Maturation of mouse NK cells is a 4-stage developmental program. Blood 113,
5488–5496.
Colucci, F., Caligiuri, M.A., and Di Santo, J.P. (2003). What does it take tomake
a natural killer? Nat. Rev. Immunol. 3, 413–425.
Cooper, M.A., Fehniger, T.A., andCaligiuri, M.A. (2001a). The biology of human
natural killer-cell subsets. Trends Immunol. 22, 633–640.
Cooper, M.A., Fehniger, T.A., Turner, S.C., Chen, K.S., Ghaheri, B.A., Ghayur,
T., Carson, W.E., and Caligiuri, M.A. (2001b). Human natural killer cells: a
unique innate immunoregulatory role for the CD56(bright) subset. Blood 97,
3146–3151.
de Andrade, L.F., Smyth, M.J., and Martinet, L. (2014). DNAM-1 control of
natural killer cells functions through nectin and nectin-like proteins. Immunol.
Cell Biol. 92, 237–244.
El-Sherbiny, Y.M., Meade, J.L., Holmes, T.D., McGonagle, D., Mackie, S.L.,
Morgan, A.W., Cook, G., Feyler, S., Richards, S.J., Davies, F.E., et al. (2007).
The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-
mediated killing of myeloma cells. Cancer Res. 67, 8444–8449.
Fauriat, C., Long, E.O., Ljunggren, H.G., and Bryceson, Y.T. (2010). Regulation
of human NK-cell cytokine and chemokine production by target cell recogni-
tion. Blood 115, 2167–2176.
Fehniger, T.A., Suzuki, K., Ponnappan, A., VanDeusen, J.B., Cooper, M.A.,
Florea, S.M., Freud, A.G., Robinson, M.L., Durbin, J., and Caligiuri, M.A.
(2001). Fatal leukemia in interleukin 15 transgenic mice follows early
expansions in natural killer and memory phenotype CD8+ T cells. J. Exp. Med.
193, 219–231.
Gasteiger, G., Hemmers, S., Bos, P.D., Sun, J.C., and Rudensky, A.Y. (2013).
IL-2-dependent adaptive control of NK cell homeostasis. J. Exp. Med. 210,
1179–1187.
Gilfillan, S., Chan, C.J., Cella, M., Haynes, N.M., Rapaport, A.S., Boles, K.S.,
Andrews, D.M., Smyth, M.J., and Colonna, M. (2008). DNAM-1 promotes acti-
vation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells
and tumors. J. Exp. Med. 205, 2965–2973.
Gilmour, K.C., Fujii, H., Cranston, T., Davies, E.G., Kinnon, C., and Gaspar,
H.B. (2001). Defective expression of the interleukin-2/interleukin-15 receptor
beta subunit leads to a natural killer cell-deficient form of severe combined
immunodeficiency. Blood 98, 877–879.
Hayakawa, Y., and Smyth, M.J. (2006). CD27 dissectsmature NK cells into two
subsets with distinct responsiveness andmigratory capacity. J. Immunol. 176,
1517–1524.
Hayakawa, Y., Huntington, N.D., Nutt, S.L., and Smyth, M.J. (2006). Functional
subsets of mouse natural killer cells. Immunol. Rev. 214, 47–55.
Huang, Z., Fu, B., Zheng, S.G., Li, X., Sun, R., Tian, Z., and Wei, H. (2011).
Involvement of CD226+ NK cells in immunopathogenesis of systemic lupus
erythematosus. J. Immunol. 186, 3421–3431.
Huntington, N.D., Vosshenrich, C.A., and Di Santo, J.P. (2007a). Develop-
mental pathways that generate natural-killer-cell diversity inmice and humans.
Nat. Rev. Immunol. 7, 703–714.
Huntington, N.D., Tabarias, H., Fairfax, K., Brady, J., Hayakawa, Y., Degli-Es-
posti, M.A., Smyth, M.J., Tarlinton, D.M., and Nutt, S.L. (2007b). NK cell matu-
ration and peripheral homeostasis is associated with KLRG1 up-regulation.
J. Immunol. 178, 4764–4770.
Huntington, N.D., Puthalakath, H., Gunn, P., Naik, E., Michalak, E.M., Smyth,
M.J., Tabarias, H., Degli-Esposti, M.A., Dewson, G., Willis, S.N., et al. (2007c).
Interleukin 15-mediated survival of natural killer cells is determined by interac-
tions among Bim, Noxa and Mcl-1. Nat. Immunol. 8, 856–863.
Huntington, N.D., Legrand, N., Alves, N.L., Jaron, B., Weijer, K., Plet, A., Cor-
cuff, E., Mortier, E., Jacques, Y., Spits, H., and Di Santo, J.P. (2009). IL-15
trans-presentation promotes human NK cell development and differentiation
in vivo. J. Exp. Med. 206, 25–34.
Iguchi-Manaka, A., Kai, H., Yamashita, Y., Shibata, K., Tahara-Hanaoka, S.,
Honda, S., Yasui, T., Kikutani, H., Shibuya, K., and Shibuya, A. (2008). Accel-
erated tumor growth in mice deficient in DNAM-1 receptor. J. Exp. Med. 205,
2959–2964.
Joly, E., and Hudrisier, D. (2003). What is trogocytosis and what is its purpose?
Nat. Immunol. 4, 815.
Kim, S., Iizuka, K., Kang, H.S., Dokun, A., French, A.R., Greco, S., and Yo-
koyama, W.M. (2002). In vivo developmental stages in murine natural killer
cell maturation. Nat. Immunol. 3, 523–528.
Kim, J.M., Rasmussen, J.P., and Rudensky, A.Y. (2007). Regulatory T cells
prevent catastrophic autoimmunity throughout the lifespan of mice. Nat.
Immunol. 8, 191–197.
Lakshmikanth, T., Burke, S., Ali, T.H., Kimpfler, S., Ursini, F., Ruggeri, L., Ca-
panni, M., Umansky, V., Paschen, A., Sucker, A., et al. (2009). NCRs and
DNAM-1 mediate NK cell recognition and lysis of human and mouse mela-
noma cell lines in vitro and in vivo. J. Clin. Invest. 119, 1251–1263.
Lee, G.A., Liou, Y.H., Wang, S.W., Ko, K.L., Jiang, S.T., and Liao, N.S. (2011).
Different NK cell developmental events require different levels of IL-15 trans-
presentation. J. Immunol. 187, 1212–1221.
Lucas, M., Schachterle, W., Oberle, K., Aichele, P., and Diefenbach, A. (2007).
Dendritic cells prime natural killer cells by trans-presenting interleukin 15.
Immunity 26, 503–517.
Mamessier, E., Sylvain, A., Thibult, M.L., Houvenaeghel, G., Jacquemier, J.,
Castellano, R., Gonc¸alves, A., Andre´, P., Romagne´, F., Thibault, G., et al.
(2011). Human breast cancer cells enhance self tolerance by promoting
evasion from NK cell antitumor immunity. J. Clin. Invest. 121, 3609–3622.Marc¸ais, A., Cherfils-Vicini, J., Viant, C., Degouve, S., Viel, S., Fenis, A., Rabil-
loud, J., Mayol, K., Tavares, A., Bienvenu, J., et al. (2014). The metabolic
checkpoint kinase mTOR is essential for IL-15 signaling during the develop-
ment and activation of NK cells. Nat. Immunol. 15, 749–757.
Nabekura, T., Kanaya, M., Shibuya, A., Fu, G., Gascoigne, N.R., and Lanier,
L.L. (2014). Costimulatory molecule DNAM-1 is essential for optimal differen-
tiation of memory natural killer cells during mouse cytomegalovirus infection.
Immunity 40, 225–234.
Narni-Mancinelli, E., Chaix, J., Fenis, A., Kerdiles, Y.M., Yessaad, N., Rey-
nders, A., Gregoire, C., Luche, H., Ugolini, S., Tomasello, E., et al. (2011).
Fate mapping analysis of lymphoid cells expressing the NKp46 cell surface re-
ceptor. Proc. Natl. Acad. Sci. USA 108, 18324–18329.
Pende, D., Castriconi, R., Romagnani, P., Spaggiari, G.M., Marcenaro, S.,
Dondero, A., Lazzeri, E., Lasagni, L., Martini, S., Rivera, P., et al. (2006).
Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor
(CD155), on dendritic cells: relevance for natural killer-dendritic cell interac-
tion. Blood 107, 2030–2036.
Ramsbottom, K.M., Hawkins, E.D., Shimoni, R., McGrath, M., Chan, C.J., Rus-
sell, S.M., Smyth, M.J., and Oliaro, J. (2014). Cutting edge: DNAX accessory
molecule 1-deficient CD8+ T cells display immunological synapse defects
that impair antitumor immunity. J. Immunol. 192, 553–557.
Raulet, D.H. (2004). Interplay of natural killer cells and their receptors with the
adaptive immune response. Nat. Immunol. 5, 996–1002.
Sanchez-Correa, B., Gayoso, I., Bergua, J.M., Casado, J.G., Morgado, S., Sol-
ana, R., and Tarazona, R. (2012). Decreased expression of DNAM-1 on NK
cells from acute myeloid leukemia patients. Immunol. Cell Biol. 90, 109–115.
Seth, S., Georgoudaki, A.M., Chambers, B.J., Qiu, Q., Kremmer, E., Maier,
M.K., Czeloth, N., Ravens, I., Foerster, R., and Bernhardt, G. (2009). Heteroge-
neous expression of the adhesion receptor CD226 on murine NK and
T cells and its function in NK-mediated killing of immature dendritic cells.
J. Leukoc. Biol. 86, 91–101.
Seth, S., Qiu, Q., Danisch, S., Maier, M.K., Braun, A., Ravens, I., Czeloth, N.,
Hyde, R., Dittrich-Breiholz, O., Fo¨rster, R., and Bernhardt, G. (2011). Intranodal
interaction with dendritic cells dynamically regulates surface expression of the
co-stimulatory receptor CD226 protein on murine T cells. J. Biol. Chem. 286,
39153–39163.
Shibuya, A., Campbell, D., Hannum, C., Yssel, H., Franz-Bacon, K.,
McClanahan, T., Kitamura, T., Nicholl, J., Sutherland, G.R., Lanier, L.L., and
Phillips, J.H. (1996). DNAM-1, a novel adhesion molecule involved in the
cytolytic function of T lymphocytes. Immunity 4, 573–581.
Spits, H., Artis, D., Colonna, M., Diefenbach, A., Di Santo, J.P., Eberl, G.,
Koyasu, S., Locksley, R.M., McKenzie, A.N., Mebius, R.E., et al. (2013). Innate
lymphoid cells—a proposal for uniform nomenclature. Nat. Rev. Immunol. 13,
145–149.
Stanietsky, N., Rovis, T.L., Glasner, A., Seidel, E., Tsukerman, P., Yamin, R.,
Enk, J., Jonjic, S., and Mandelboim, O. (2013). Mouse TIGIT inhibits NK-cell
cytotoxicity upon interaction with PVR. Eur. J. Immunol. 43, 2138–2150.
Stewart, C.A., Walzer, T., Robbins, S.H., Malissen, B., Vivier, E., and Prinz, I.
(2007). Germ-line and rearranged Tcrd transcription distinguish bona fide NK
cells and NK-like gammadelta T cells. Eur. J. Immunol. 37, 1442–1452.
Vesely, M.D., Kershaw, M.H., Schreiber, R.D., and Smyth, M.J. (2011). Natural
innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29, 235–271.
Vivier, E., Tomasello, E., Baratin, M., Walzer, T., and Ugolini, S. (2008). Func-
tions of natural killer cells. Nat. Immunol. 9, 503–510.
Vosshenrich, C.A., Ranson, T., Samson, S.I., Corcuff, E., Colucci, F., Rosmar-
aki, E.E., and Di Santo, J.P. (2005). Roles for common cytokine receptor
gamma-chain-dependent cytokines in the generation, differentiation, and
maturation of NK cell precursors and peripheral NK cells in vivo. J. Immunol.
174, 1213–1221.
Walzer, T., Ble´ry, M., Chaix, J., Fuseri, N., Chasson, L., Robbins, S.H., Jaeger,
S., Andre´, P., Gauthier, L., Daniel, L., et al. (2007). Identification, activation, and
selective in vivo ablation of mouse NK cells via NKp46. Proc. Natl. Acad. Sci.
USA 104, 3384–3389.Cell Reports 11, 85–97, April 7, 2015 ª2015 The Authors 97
